---
document_datetime: 2025-09-08 15:13:41
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lopinavir-ritonavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lopinavir-ritonavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7366106
conversion_datetime: 2025-12-28 08:24:20.63859
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lopinavir/Ritonavir Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 05/09/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291122   | variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes   |            |     | PL   |                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-------------------|
| Variation type IB / | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/07/2025 | N/A |      | EMA/VR/0000268655 |

<div style=\"page-break-after: always\"></div>

|                                                         | No 1234/2008. B.II.e) Container closure system - B.II.e.z Other variation - Accepted                                                                                                                                                                            |            |            |                        |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Article 61(3) / EMA/N/0000256687                        | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4. | 26/03/2025 |            | PL                     |
| Marketing Authorisation Transfer - H / EMA/T/0000178558 | - Transfer of a marketing authorisation - Accepted Transfer of Marketing Authorisation from Mylan Pharmaceuticals Limited to Viatris Limited.                                                                                                                   | 31/05/2024 | 29/07/2024 | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000174634                | A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted                                                                                                                                                | 18/04/2024 | 13/06/2024 | SmPC, Labelling and PL |